313 related articles for article (PubMed ID: 16166615)
21. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis.
Cunningham S; McColm JR; Mallinson A; Boyd I; Marshall TG
Pediatr Pulmonol; 2003 Jul; 36(1):43-8. PubMed ID: 12772222
[TBL] [Abstract][Full Text] [Related]
22. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy.
Colombo C; Costantini D; Rocchi A; Cariani L; Garlaschi ML; Tirelli S; Calori G; Copreni E; Conese M
Pediatr Pulmonol; 2005 Jul; 40(1):15-21. PubMed ID: 15858808
[TBL] [Abstract][Full Text] [Related]
23. Dornase alfa in early cystic fibrosis lung disease.
Robinson PJ
Pediatr Pulmonol; 2002 Sep; 34(3):237-41. PubMed ID: 12203856
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry.
Zemel BS; Jawad AF; FitzSimmons S; Stallings VA
J Pediatr; 2000 Sep; 137(3):374-80. PubMed ID: 10969263
[TBL] [Abstract][Full Text] [Related]
25. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis.
Ordoñez CL; Kartashov AI; Wohl ME
J Pediatr; 2004 Nov; 145(5):689-92. PubMed ID: 15520781
[TBL] [Abstract][Full Text] [Related]
26. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.
Amadori A; Antonelli A; Balteri I; Schreiber A; Bugiani M; De Rose V
Respir Med; 2009 Mar; 103(3):407-13. PubMed ID: 19027279
[TBL] [Abstract][Full Text] [Related]
27. Relationship between sputum inflammatory markers, lung function, and lung pathology on high-resolution computed tomography in children with cystic fibrosis.
Dakin CJ; Pereira JK; Henry RL; Wang H; Morton JR
Pediatr Pulmonol; 2002 Jun; 33(6):475-82. PubMed ID: 12001282
[TBL] [Abstract][Full Text] [Related]
28. Exhaled breath condensate pH and ammonia in cystic fibrosis and response to treatment of acute pulmonary exacerbations.
Newport S; Amin N; Dozor AJ
Pediatr Pulmonol; 2009 Sep; 44(9):866-72. PubMed ID: 19670404
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis of nasal cells from cystic fibrosis patients and non-cystic fibrosis control individuals: search for novel biomarkers of cystic fibrosis lung disease.
Roxo-Rosa M; da Costa G; Luider TM; Scholte BJ; Coelho AV; Amaral MD; Penque D
Proteomics; 2006 Apr; 6(7):2314-25. PubMed ID: 16518875
[TBL] [Abstract][Full Text] [Related]
30. Patient indicators of a pulmonary exacerbation: preliminary reports from school aged children map onto those of adults.
Abbott J; Holt A; Morton AM; Hart A; Milne G; Wolfe SP; Conway SP
J Cyst Fibros; 2012 May; 11(3):180-6. PubMed ID: 22172941
[TBL] [Abstract][Full Text] [Related]
31. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
[TBL] [Abstract][Full Text] [Related]
32. Increased arginase activity in cystic fibrosis airways.
Grasemann H; Schwiertz R; Matthiesen S; Racké K; Ratjen F
Am J Respir Crit Care Med; 2005 Dec; 172(12):1523-8. PubMed ID: 16166623
[TBL] [Abstract][Full Text] [Related]
33. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function.
Eickmeier O; Huebner M; Herrmann E; Zissler U; Rosewich M; Baer PC; Buhl R; Schmitt-Grohé S; Zielen S; Schubert R
Cytokine; 2010 May; 50(2):152-7. PubMed ID: 20181491
[TBL] [Abstract][Full Text] [Related]
34. Imbalance between 95 kDa type IV collagenase and tissue inhibitor of metalloproteinases in sputum of patients with cystic fibrosis.
Delacourt C; Le Bourgeois M; D'Ortho MP; Doit C; Scheinmann P; Navarro J; Harf A; Hartmann DJ; Lafuma C
Am J Respir Crit Care Med; 1995 Aug; 152(2):765-74. PubMed ID: 7633740
[TBL] [Abstract][Full Text] [Related]
35. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis.
Nick JA; Sanders LA; Ickes B; Briones NJ; Caceres SM; Malcolm KC; Brayshaw SJ; Chacon CS; Barboa CM; Jones MC; St Clair C; Taylor-Cousar JL; Nichols DP; Sagel SD; Strand M; Saavedra MT
Thorax; 2013 Oct; 68(10):929-37. PubMed ID: 23783371
[TBL] [Abstract][Full Text] [Related]
36. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.
Laguna TA; Wagner BD; Luckey HK; Mann SA; Sagel SD; Regelmann W; Accurso FJ
Chest; 2009 Dec; 136(6):1561-1568. PubMed ID: 19567495
[TBL] [Abstract][Full Text] [Related]
37. Peroxidase activity within circulating neutrophils correlates with pulmonary phenotype in cystic fibrosis.
Garner HP; Phillips JR; Herron JG; Severson SJ; Milla CE; Regelmann WE
J Lab Clin Med; 2004 Sep; 144(3):127-33. PubMed ID: 15454881
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
39. Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis.
Olesen HV; Holmskov U; Schiøtz PO; Sørensen GL
J Cyst Fibros; 2010 Jul; 9(4):257-62. PubMed ID: 20457545
[TBL] [Abstract][Full Text] [Related]
40. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
